Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
National Cancer Institute (NCI)
Phase 1
2024-05-20
This phase I trial studies the side effects and best dose of mosunetuzumab when given
together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large
B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that
has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin
are monoclonal antibodies that may interfere with the ability of cancer cells to grow and
spread. Polatuzumab, linked to a toxic agent called vedotin, attaches to CD79B positive
cancer cells in a targeted way and delivers vedotin to kill them. Lenalidomide may stimulate
or suppress the immune system in different ways and stop cancer cells from growing and by
preventing the growth of new blood vessels that cancer cells need to grow. Giving
mosunetuzumab with polatuzumab vedotin and lenalidomide may work better in treating patients
with relapsed/refractory DLBCL.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
